Search

Author/Creator Tada, Y.

2. A case of type 1 segmental Darier disease showing widespread Blaschkoid skin lesions with p.P160L mutation in ATP2A2. (8th June 2020)

Authors:
Agematsu, A.; Kamata, M.; Uchida, H.; Nagata, M.; Fukaya, S.; Hayashi, K.; Fukuyasu, A.; Tanaka, T.; Ishikawa, T.; Ohnishi, T.; Tada, Y.; Kubo, A.
Journal:
Journal of the European Academy of Dermatology and Venereology
Issue:
Volume 34:Number 10(2020)
Page Start:
e633
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (15th January 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.
Other Names:
Vender Ronald investigator.; Lomaga Mark A. investigator.; Delorme Isabelle investigator.; Hong Chih‐Ho investigator.; Langley Richard L. investigator.; Albrecht Lorne investigator.; Guenther Lyn investigator.; Maari Catherine investigator.; Papp Kim investigator.; Singh Ohson Kamal K. investigat...
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. (1st June 2020)

Authors:
Blauvelt, A.; Papp, K.; Gottlieb, A.; Jarell, A.; Reich, K.; Maari, C.; Gordon, K.B.; Ferris, L.K.; Langley, R.G.; Tada, Y.; Lima, R.G.; Elmaraghy, H.; Gallo, G.; Renda, L.; Park, S.Y.; Burge, R.; Bagel, J.; Vender, Ronald; Lomaga, Mark A.; Delorme, Isabelle
Journal:
British journal of dermatology
Issue:
Volume 182:Number 6(2020)
Page Start:
1348
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. (1st June 2021)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (1st June 2021)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial. (25th October 2020)

Authors:
Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.J.; Guenther, L.C.; Gooderham, M.; Langley, R.G.; Vender, R.; Pinter, A.; Griffiths, C.E.M.; Tada, Y.; Elmaraghy, H.; Lima, R.G.; Gallo, G.; Renda, L.; Burge, R.; Park, S.Y.; Zhu, B.; Papp, K.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 6(2021)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A possible contribution of lipocalin‐2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. (11th June 2015)

Authors:
Takahashi, T.; Asano, Y.; Noda, S.; Aozasa, N.; Akamata, K.; Taniguchi, T.; Ichimura, Y.; Toyama, T.; Sumida, H.; Kuwano, Y.; Tada, Y.; Sugaya, M.; Kadono, T.; Sato, S.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 3(2015:Sep.)
Page Start:
681
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A possible contribution of lipocalin‐2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. (11th June 2015)

Authors:
Takahashi, T.; Asano, Y.; Noda, S.; Aozasa, N.; Akamata, K.; Taniguchi, T.; Ichimura, Y.; Toyama, T.; Sumida, H.; Kuwano, Y.; Tada, Y.; Sugaya, M.; Kadono, T.; Sato, S.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 3(2015:Sep.)
Page Start:
681
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. A possible contribution of lipocalin‐2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. (1st September 2015)

Authors:
Takahashi, T.; Asano, Y.; Noda, S.; Aozasa, N.; Akamata, K.; Taniguchi, T.; Ichimura, Y.; Toyama, T.; Sumida, H.; Kuwano, Y.; Tada, Y.; Sugaya, M.; Kadono, T.; Sato, S.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 3(2015:Sep.)
Page Start:
681
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗